1 min read
Add as a preferred source on GoogleInsight Molecular Diagnostics to Report Q3 Results Nov. 16
Consensus estimates put earnings per share at a loss of $0.22, with a reported 35.3% year-over-year increase. Revenue is projected at $240,000, down 7.7%.
Insight Molecular Diagnostics Inc. (IMDX) is scheduled to release third-quarter results after the market closes Monday, Nov. 16, with consensus estimates calling for a per-share loss and lower revenue.
The consensus earnings-per-share estimate is a loss of $0.22, with a 35.3% year-over-year increase. Revenue is forecast at $240,000, down 7.7% from a year earlier.
The company’s shares trade on Nasdaq.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.